Vifor Pharma is a fully integrated specialty pharma company of the Galenica Group. The company operates in three franchises: Iron, Vifor Fresenius Medical Care Renal Pharma Ltd. and Infectious Diseases / OTX.
The iron franchise focuses its activities on iron deficiency with or without anaemia, a globally widespread ailment. Key brands in the iron replacement product portfolio of Vifor Pharma are Ferinject®, Venofer® and Maltofer®. The intravenous and oral iron replacement therapies serve the following therapeutic areas: haemodialysis, non-dialysis chronic kidney diseases (ND-CKD), cardiology, oncology, obstetrics and gynaecology, gastroenterology, patient blood management, women’s health and paediatrics. To provide scientific evidence for the efficiency and safety of intravenous iron therapy in these patients, Vifor Pharma has a comprehensive clinical and scientific development programme in place.
For more information visit the iron therapies section
Vifor Fresenius Medical Care Renal Pharma Ltd. is a strategic partnership between Vifor Pharma and Fresenius Medical Care.
To strengthen its position in the global intravenous iron market Vifor Pharma first joined forces with Fresenius Medical Care, the world leader in dialysis products and services in 2008 with exclusive licence agreements for the commercialisation of Venofer® and Ferinject® for iron deficiency anaemia in haemodialysis in the USA, Europe, the Middle East, Africa and Latin America.
In December 2010 Vifor Pharma and Fresenius Medical Care announced an extension of their partnership through the creation of a specialty pharmaceuticals company, Vifor Fresenius Medical Care Renal Pharma Ltd. The new nephrology company develops and commercialises innovative and high-quality products to improve the lives of patients suffering from chronic kidney disease worldwide.
The Infectious Diseases / OTX product portfolio is made up of about 10 products and includes products for brain function and development, ear care, abdominal distension, chronic obstructive pulmonary disease, respiratory tract Infections, lower urinary tract infections, chronic venous insufficiency, diabetic retinopathy, haemorrhoids, menometrorrhagia or heavy menstrual bleeding.
The key brands are Otalgan®, Aero-OM®, Broncho-Vaxom®, Uro-Vaxom®, Doxium® and Dicynone®.
Vifor Pharma continues to internationalise the product range. The majority of sales come from approximately 100 countries in Europe, Asia, Africa, Latin America and the Middle East.
Visit the Infectious Diseases / OTX products section
The development and production of products for third parties, contract development and contract manufacturing, is another pillar of Vifor Pharma’s business. We use our diversified manufacturing equipment for the production of solid, semi-solid and liquid forms.
For more information click here.